PTGX Stock Summary and Trading Ideas (Protagonist Therapeutics | NASDAQ:PTGX)

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Protagonist Therapeutics trades on the NASDAQ stock market under the symbol PTGX.

As of April 19, 2024, PTGX stock price climbed to $25.61 with 422,830 million shares trading.

PTGX has a beta of 1.43, meaning it tends to be more sensitive to market movements. PTGX has a correlation of 0.10 to the broad based SPY ETF.

PTGX has a market cap of $1.47 billion. This is considered a Small Cap stock.

Last quarter Protagonist Therapeutics reported $60 million in Revenue and $.44 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.47.

In the last 3 years, PTGX stock traded as high as $50.54 and as low as $6.91.

The top ETF exchange traded funds that PTGX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.

PTGX has underperformed the market in the last year with a price return of +10.3% while the SPY ETF gained +21.2%. However, in the short term, PTGX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.9% vs +4.3% return in SPY. But in the last 2 weeks, PTGX shares have been beat by the market, returning -7.4% compared to an SPY return of -3.5%.

PTGX support price is $24.59 and resistance is $25.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTGX stock will trade within this expected range on the day.